Interleukin 1 beta

Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient

Retrieved on: 
Thursday, June 9, 2022
Cerebellum, Hospital, Gamma ray, PET, Vital signs, COVID, Research, HIV disease progression rates, SMPS, Board of High School and Intermediate Education Uttar Pradesh, Pharmacokinetics, White matter, Annual report, Neurodegeneration, Sclerosis, Disease, Interleukin 1 beta, Type 1 diabetes, Inflammation, Blood, IND, Brain, FDA, GLOBE, Patient, Pulmonary fibrosis, Nasal administration, RESEARCH, Harvard University, Zacks, Immune system, Incidence, Compliance, KOL, NASDAQ, Cytokine, IL-6, Multiple sclerosis, NSCLC, 40, Authorization, Safety, Thalamus, Medical imaging, Pharmaceutical industry, Vaccine, SPMS, Foralumab

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second secondary progressive multiple sclerosis (SMPM) patient in a June 8th press release. The ~40 year old individual that was enrolled as the second patient in the trial exhibited clinical improvements on several measures, including positron emission tomography (PET) analysis, neurologic exam and the timed 25-foot walk test after three months of treatment. The results from the second patient are consistent with the results from the first patient which were reported in a March 10 press release. Based on the data gathered from the first two subjects, Tiziana has requested and the FDA has cleared enrollment of eight more eligible SMPS patients to receive intranasal foralumab, a fully human anti-CD3 monoclonal antibody therapy, under the Expanded Access Program.

Key Points: 
  • The second patient was diagnosed with SPMS in 2014 and over the subsequent eight years, the magnitude of his disability increased.
  • See link here for the discussion on the results for the first patient and detailed background on SPMS.
  • In the clinical sphere, investigators observed improvements in the 25-foot walk test and the neurologic exam for patient #2.
  • Intranasal Foralumabs First SPMS Patient: 3- and 6-Month Data, KOL Discussion
    On January 10, 2022, Tiziana provided a progress update for its first patient in the evaluation of intranasal foralumab in SPMS.

Clinical Evaluation of LeSoleil Against COVID-19

Retrieved on: 
Thursday, January 6, 2022
Nuclear, Respiration, CCL8, Respiratory tract, Severe acute respiratory syndrome coronavirus 2, COVID-19, Drug discovery, Omicron, Assay, Heme, Acquisition, Oxidative stress, H5N1, Research, Patient, Biomedical Research, IL-6, PCT, Delta, HO-1, Peroxisome, Drug design, Health, Infection, Creatinine, Inflammation, Economic development, International Drug Policy Consortium, Incidence, Interleukin 1 beta, Lymphocyte, Protocol, R, Death, Warfarin necrosis, Nrf2 internal ribosome entry site (IRES), Pharmaceutical industry, Vaccine, H7N9, SunTrap, H1N1

The Suntrap team believes that the prevention and treatment of COVID-19 should focus on the development of multi-targeted and broad-spectrum anti-coronavirus drugs.

Key Points: 
  • The Suntrap team believes that the prevention and treatment of COVID-19 should focus on the development of multi-targeted and broad-spectrum anti-coronavirus drugs.
  • Based on the clinical symptoms and pathogenic mechanism of patients infected with SARS-CoV-2, the Suntrap research team optimized and developed different clinical protocols.
  • LeSoleil broad-spectrum anti-coronavirus protective and therapeutic spray can cope with the prevention and treatment of SARS-CoV-2 and variant strains (e.g., Delta and Omicron.).
  • To further in-depth clinical research of LeSoleil anti-SARS-CoV-2 drugs, and deter COVID-19 as an obstacle for social stability, economic development and human health, Suntrap recruits qualified clinical research institutions around the world to carry out clinical evaluation studies on the efficacy of the LeSoleil broad-spectrum anti-coronavirus drug series against mutant strains of SARS-CoV-2.

Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still's disease

Retrieved on: 
Thursday, April 29, 2021
Clinical medicine, Medicine, Medical specialties, Canakinumab, Immunology, Novartis, AOSD, Interleukin 1 beta, Monoclonal antibody, Adult-onset Still's disease

b'The approval of Ilaris (canakinumab) in the treatment of adult-onset Still\'s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.\nDORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris (canakinumab) for the treatment of active Still\'s disease, including adult-onset Still\'s disease (AOSD)1.

Key Points: 
  • b'The approval of Ilaris (canakinumab) in the treatment of adult-onset Still\'s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.\nDORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris (canakinumab) for the treatment of active Still\'s disease, including adult-onset Still\'s disease (AOSD)1.
  • "We are proud to announce this latest approval for Ilaris and are hopeful that it will open the door to reimagining care for adult Canadian patients.
  • "\nIlaris is a genetically engineered high-affinity human anti-human-interleukin-1 beta (IL-1) monoclonal antibody, administered by subcutaneous injection every four weeks in the treatment of AOSD1.
  • In our quest to find new medicines, we consistently rank among the world\'s top companies investing in research and development.

Inflammasome Therapeutics Says Study of Approximately 130,000 People Reported in Nature Communications Points to Potential for Treatment or Prevention of Diabetes and Other Inflammasome-Mediated Diseases with Company’s Drugs

Retrieved on: 
Wednesday, September 23, 2020
Biotechnology, General Health, Health, Pharmaceutical, Clinical trials, Branches of biology, Proteins, Macular degeneration, RTT, Senescence, Inflammasome, Reverse-transcriptase inhibitor, Organ systems, Interleukin 1 beta, NLRP3

This study follows a preclinical study led by Dr. Ambati in 2014 showing NRTIs were efficacious in macular degeneration (AMD) in non-human models.

Key Points: 
  • This study follows a preclinical study led by Dr. Ambati in 2014 showing NRTIs were efficacious in macular degeneration (AMD) in non-human models.
  • NRTIs, in addition to their anti-viral effects also inhibit activation of a specific part of the immune system, the inflammasome.
  • Inflammasome activation is thought to promote many chronic diseases such as diabetes, macular degeneration, Alzheimers disease and multiple sclerosis.
  • This study shows, in a very large clinical data set, the potential for inhibiting inflammasome activation to treat diabetes.

Inflammasome Therapeutics Receives Grant to Develop Sustained-Release Bioerodible Birth Control Implant

Retrieved on: 
Wednesday, September 16, 2020
Biotechnology, Diabetes, Health, Branches of biology, Cytokines, Inflammasome, Degenerative disease, Contraceptive implant, Biology, Interleukin 1 beta

Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases as well as sustained-release drug delivery systems, announced it has been awarded a $1.0-million grant to develop a long-term bioerodible birth control implant.

Key Points: 
  • Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases as well as sustained-release drug delivery systems, announced it has been awarded a $1.0-million grant to develop a long-term bioerodible birth control implant.
  • After the drug has been fully released the implant will dissolve in the body requiring no removal as is current practice with the existing levonorgestrel implant in use today.
  • Dr. Paul Ashton, CEO of Inflammasome Therapeutics said, We are delighted to work with the foundation on this important program.
  • Inflammasome Therapeutics ( www.inflam.com ) is a science-based company founded to develop therapies for prevalent, degenerative diseases such as Alzheimers disease, multiple sclerosis, macular degeneration and type 2 diabetes.

FDA clears Abivertinib for Phase 2 safety and efficacy study in hospitalized patients with moderate to severe COVID-19

Retrieved on: 
Monday, July 20, 2020
Medical specialties, Immunology, Clinical medicine, Medicine, Cytokines, Interleukins, Cytokine release syndrome, Cytokine, Inflammatory cytokine, Tumor necrosis factor, Interleukin 1 beta, Lenzilumab

Due to this effect, it has shown potent immunomodulatory activities in vitro by inhibiting key pro-inflammatory cytokine production, including IL-1beta, IL-6 and TNF-alpha.

Key Points: 
  • Due to this effect, it has shown potent immunomodulatory activities in vitro by inhibiting key pro-inflammatory cytokine production, including IL-1beta, IL-6 and TNF-alpha.
  • These cytokines are associated with cytokine release syndrome (CRS) or cytokine storm and COVID-19 disease progression with poor outcomes in patients with acute respiratory distress syndrome (ARDS).
  • Abivertinib has been studied in over 600 patients worldwide in various oncologic indications, including one registration trial in non-small cell lung cancer.
  • RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.

FDA Grants Orphan Drug Designation for Inflazome’s Inzomelid for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Retrieved on: 
Tuesday, July 14, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Autoinflammatory syndromes, Medical specialties, Branches of biology, Health, Periodic fever syndrome, Cryopyrin-associated periodic syndrome, NALP3, Caps, Orphan drug, NLRP, Interleukin 1 beta, NLRC4, Inflazome, the NLPR3 Inflammasome, Cryopyrin-associated periodic syndromes, Orphan Drug Designation

Inflazome ( inflazome.com ), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that it has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for Inzomelid in the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS).

Key Points: 
  • Inflazome ( inflazome.com ), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that it has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for Inzomelid in the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS).
  • Orphan Drug Designation is an important regulatory milestone granted to drugs that are intended to treat rare diseases and conditions, such as CAPS.
  • Inzomelid is under development as an orally available, brain-penetrant drug and Somalix is under development as an orally available, peripherally-restricted drug.
  • Cryopyrin-associated periodic syndromes (CAPS), also called cryopyrin-associated autoinflammatory syndromes, are three diseases related to a defect in the NLRP3 gene.